Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-09-12
2006-09-12
Yu, Misook (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07105656
ABSTRACT:
Methods and compositions are provided for treating a subject having or at risk of developing a hematologic malignancy and/or multiple drug resistance.
REFERENCES:
patent: 5882914 (1999-03-01), Semenza
patent: 5968735 (1999-10-01), Stein et al.
patent: 6001991 (1999-12-01), Dean et al.
patent: 6020462 (2000-02-01), Semenza
patent: WO 96/39426 (1996-12-01), None
patent: WO 98/14615 (1998-04-01), None
patent: WO 98/20038 (1998-05-01), None
patent: WO 99/09046 (1999-02-01), None
patent: WO 00/36148 (2000-06-01), None
patent: WO 00/69908 (2000-11-01), None
patent: WO 02/02609 (2002-01-01), None
Verma et al. (Nature 1997, 389:239-242).
Izquierdo (2004, Cancer Therapy, 1-11).
Caniggia et al., “Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFB3”J. of Clinical Investigation, vol. 105, No. 5, Mar. 2000, pp. 577-587.
Comerford et al., “Hypoxia-inducible Factor-1-dependent Regulation of the Multidrug Resistance (MDRI) Gene”Cancer Research, 62, pp. 3387-3394, Jun. 15, 2002.
Semenza et al., “Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression.”Critical Reviews in Biochemistry and Molecular Biology. 35(2); 71-103 (2000).
Semenza et al., “Hypoxia-inducible factor 1: master regulator of O2homeostasis.”Current Opinion in Genetics&Development, vol. 8, No. 5. Oct. 1998. pp. 588-594.
Wallace et al. “Induction of multidrug resistance (mdr-1) gene by hypoxia,”Molecular Biology of the Cell, vol. 11, No. Supplement, Dec. 2000, p. 435a, (abstract).
Communication Relating to the Results of the Partial International Search. PCT/US01/49856, Nov. 18, 2002.
Brown, JM “Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies,”Molecular Medicine Today. 6:157-162 (Apr. 2000).
Fardel, O., et al. “The P-glycoprotein multidrug transporter.”Gen. Pharmacol., 27(8): 1283-91 (1996).
Jin, S., et al., “Transcriptional regulation of the MDRI gene by histone acetyltransferase and deacetylase is mediated by NF-Y.” Molecular and Cellular Biology 18:4377-4384 (1998).
Kaye, SB. “Multidrug resistance: clinical relevance in solid tumors and strategies for circumvention.”Curr Opin Oncol. 10(suppl. 1):S15-S19 . (1998).
Liang, BC., “Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.” J Neuro-Oncology. 29:149-155 (1996).
Ryan, HE., et al. “HIF-1 α is required for solid tumor formation and embryonic vascularization.”EMBO Journal. 17(11):3005-3015 (1998).
Semenza, GL., et al. “Regulation of mammalian O2homeostasis by hypoxia-inducible factor I.”Annu. Rev. Cell Dev Biol. 15:551-78 (1999).
Strauss, BE et al., “The region 3′ to the major transcriptional start site of the mdrl downstream promoter mediates activation by a subset of mutant P53 proteins.” Biochem Biophys Res Commun. 217(1):333-340 (1995).
Sutherland, RM “Tumor hypoxia and gene expression—implications of malignant progression and therapy.”Acta Oncol. 37(6):567-74. (1998).
Ueda. K “Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine. doxorubicin, and vinblastine.”Proc. Natl. Acad. Sci. USA84:3004-3008 (1987).
Ueda, K.. et al. “Isolation and sequence of the promoter region of the human multidrug resistance (P-glycoprotein) gene.”J. Biol. Chem. 262(36):17432-17436 (1987).
Ueda, K., et al. “The human multidrug resistance (mdr1) gene.”J. Biol. Chem. 262(2):505-508 (1987).
Ueda, K., et al. “The mdr1 gene, responsible for multidrug-resistance codes for p-glycoprotein.”Biochem Biophys Res Commun. 141(3):956-962. (1986).
Kretz-Remy et al., “SUMO/sentrin: protein modifiers regulating important cellular functions,”Biochem Cell Biol., 77: 299-309 (1999).
Mao et al., “SUMO-1 conjugation to topoisomerase 1: A possible repair response to topoisomerase-mediated DNA damage,”PNAS, 97, No. 8:4046-4051 (2000).
International Search Report for PCT/US01/49856; Date of Search: Feb. 6, 2003 (Mailed Feb. 17, 2003).
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
Yu Misook
LandOfFree
Compositions and methods for treating hematologic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating hematologic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating hematologic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3611585